Abstract: During pregnancy, maternal immune activation (MIA), due to infection, chronic inflammatory disorders, or toxic exposures, can result in lasting health impacts on the developing fetus. MIA has been associated with an increased risk of neurodevelopmental disorders, such as autism spectrum disorder (ASD) in the offspring. ASD is characterized by increased repetitive and stereotyped behaviors and decreased sociability. As of 2020, 1 in 36 children are diagnosed with ASD by the age of 8 years, with ASD rates continuing to increase in prevalence in USA (Tamayo et al., 2023). Post-mortem brain studies, biomarker and transcriptomic studies, and epidemiology studies have provided compelling evidence of immune dysregulation in the circulation and brain of individuals diagnosed with ASD. Currently, the etiology of ASD is largely unknown, however, genetic components and environmental factors can contribute to increased susceptibility. Maternal allergic asthma (MAA), a form of MIA, has been identified as a potential risk factor for developing neurodevelopmental disorders (Patel et al., 2020). Asthma is a chronic inflammatory condition driven by a T-helper type (TH) 2 immune response. As with ASD, the prevalence rates of asthma are on the rise (Gans and Gavrilova, 2020). Several population-based studies have shown a relationship between MAA and the development of ASD in the infant, however, there is currently a knowledge gap in terms of the mechanisms that underlie this relationship. Animal models have also started to build on this evidence to provide mechanistic insight and will provide a valuable tool for ongoing and future mechanistic studies.